SMN2 and spinal muscular atrophy, type 1: The SPR1NT study also reports a naïve comparison versus a matched cohort of untreated SMA type 1 patients with two copies of SMN2 (n = 23), as well as versus studies of onasemnogene abeparvovec in symptomatic SMA type 1.